Anitha, KGopi, GGirishKumar, P Senthil2013-09-162013-09-162013-08Anitha K, Gopi G, Girish, Kumar P Senthil. Molecular Docking Study on Dipeptidyl Peptidase-4 Inhibitors. International Journal of Research and Development in Pharmacy and Life Sciences. 2013 Aug-Sept; 2(5): 602-610.http://imsear.searo.who.int/handle/123456789/148290Dipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9. DPP-IV is a key regulator of incretin hormones, but the functions of other family members are unknown. To determine the importance of selective DPP-IV inhibition for the treatment of diabetes, we conducted molecular docking studies on clinical inhibitors of DPP-IV.enDPP IVDockingType 2 diabetesAutoDockArticle